Novo Nordisk partners with AWS to accelerate AI-driven drug discovery

Reuters2026/08/10 12:02

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Novo Nordisk struck a strategic partnership with AWS to accelerate drug discovery using agentic AI and cloud technology.
A new co-innovation hub in London will embed AWS engineers and scientists with Novo Nordisk R&D to shorten timelines from target to first human dose.
AWS becomes Novo Nordisk’s preferred cloud provider and strategic AI partner as the drugmaker modernizes its technology infrastructure.
The companies cited early gains, including shorter clinical documentation time and AI tools rolled out to more than 25,000 employees.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novo Nordisk A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608100800OMX_____CNEWS_EN_GNW1001256832_en) on August 10, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Novo Nordisk partners with AWS to accelerate AI-driven drug discovery

You may also like

Crypto prices